secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001628280-24-041432
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive completes Anaphylm oral allergen challenge enrollment; unveils AQST-108 Phase 2 for alopecia areata
--------------------------------------------------------------------------------

- Anaphylm (epinephrine sublingual film) oral allergen challenge study fully enrolled; topline data expected Q4 2024.
- Pre-NDA meeting request submitted to FDA; NDA submission planned for Q1 2025, launch by end-2025 or early 2026.
- AQST-108 (epinephrine topical gel) first human study completed: no serious adverse events, zero plasma drug levels observed.
- AQST-108 to be developed for alopecia areata (6.7M US patients); Phase 2 design outlined for mild-to-moderate disease.
- Pre-IND meeting for AQST-108 targeted Q1 2025; Phase 2 initiation expected H2 2025 pending FDA alignment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024041432/0001628280-24-041432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024041432/aqst-20240927.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-041432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer